IRB #

IRB00007565

Title

ET743-SAR-3007, A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare the effects, good and/or bad of the study drug, trabectedin, with the commonly used drug Dacarbazine to find out which is better.

Medical Condition(s)

Soft Tissue

Eligibility Criteria

*Subjects must be 15 years of age or older.
*Subjects must have a diagnosis of either cancer of fat cells or cancer of smooth muscle.
*Have had prior anti-cancer treatment.
*Subject's medical history will be reviewed in detail for study eligibility.

Age Range

15 - 100

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Recruitment End

Compensation Provided

No